A pediatric oncologist colleague of ours from Cornell Medical Center in New York posted a question to Facebook on March 23, 2020: How would the new COVID-19 pandemic impact the pediatric cancer population? We were asking ourselves the same question here at Children’s of Alabama. As social distancing and virtual meetings became the norm, we put our heads together – nearly 1,000 miles apart – to figure out how best to provide ongoing care for our oncology patients.
The result is the Pediatric COVID-19 Cancer Case (POCC) Report, a national registry of pediatric cancer patients diagnosed with COVID-19. It’s designed to better help our fellow clinicians provide vital care during an evolving pandemic.
Multiple Myeloma is a hematologic cancer of the plasma cells, which are found in the bone marrow. Early symptoms of Multiple Myeloma include fatigue, back pain and bone pain. Because these symptoms are non-specific, patients often go first to their primary care physician which can delay diagnosis, resulting in a more progressive disease. This year alone, the American Cancer Society predicts 34,920 new cases and 12,410 expected deaths from Multiple Myeloma.
October brings many welcome changes, including cooler temperatures, colorful leaves and the return of fall sports. As a breast-specialized radiologist, I look forward to October events designed to promote breast cancer screening awareness. Public campaigns, corporate promotions and community awareness events all contribute to this effort. I’m always happy to see those annual mammography patients who have established themselves as “October regulars” as a result of these efforts.
Annual mammography has been shown to decrease breast cancer death by at least 40 percent.
As the new division director of the Pediatric Hematology-Oncology and Blood Marrow Transplantation program in the University of Alabama at Birmingham (UAB) Department of Pediatrics and Children’s of Alabama, my top priority is to build a well-rounded program; a program that is not only strong in its clinical mission – to provide the best treatment possible for children with cancer and blood diseases – but one that also has a strong research base, which includes clinical, basic and translational research.
As financial advisors, we help our clients to consider and plan not only for their own goals, but also for some of life’s serious “what ifs.” What if you want to retire early? What if you want to buy a vacation home? What if your child is planning to attend graduate school? What if you need long-term care? What if you are raising a young family and you get cancer?
The field of oncodermatology has emerged as a result of remarkable advances in cancer treatment. Unlike traditional chemotherapy, targeted anticancer agents such as epidermal growth factor receptor (EGFR) inhibitors are associated with decreased systemic toxicities.
For 2017, The American Cancer Society has estimated that around 252,710 new cases of invasive breast cancer will be diagnosed in women and 2,470 diagnosed in men, around 63,410 new cases of Carcinoma in situ(non-invasive and the earliest form of breast cancer) will be diagnosed, and approximately 40,610 cases will be fatal.
Did you know that prostate cancer is the second most common cancer among American men? In fact, an average of 480 American men are diagnosed with prostate cancer every day - that’s one every 3 minutes.
Prostate cancer is the second most common cancer diagnosed in American men and the second leading cause of cancer death. While a majority of men will be diagnosed after the age of 65, younger men do need to consider screening for prostate cancer, especially if risk factors are present such as African American heritage or a family history of prostate cancer.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: